BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2018-12-12
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of
up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.